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Abstract
Supratentorial ependymoma (ST-EPN) is a type of malignant brain tumor mainly seen in children. Since 2014, it has been 
known that an intrachromosomal fusion C11orf95-RELA is an oncogenic driver in ST-EPN [Parker et al. Nature 506:451–455 
(2014); Pietsch et al. Acta Neuropathol 127:609–611 (2014)] but the molecular mechanisms of oncogenesis are unclear. 
Here we show that the C11orf95 component of the fusion protein dictates DNA binding activity while the RELA component 
is required for driving the expression of ependymoma-associated genes. Epigenomic characterizations using ChIP-seq and 
HiChIP approaches reveal that C11orf95-RELA modulates chromatin states and mediates chromatin interactions, leading to 
transcriptional reprogramming in ependymoma cells. Our findings provide important characterization of the molecular under-
pinning of C11orf95-RELA fusion and shed light on potential therapeutic targets for C11orf95-RELA subtype ependymoma.
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Introduction
Ependymoma is the third most common malignant brain 
tumor in children. It can be classified into three groups based 
on location of the tumor: supratentorial, infratentorial and 
spinal. Currently there is no effective chemotherapy iden-
tified and treatment is limited to surgery with or without 
adjuvant radiation therapy. Because a significant portion of 
ependymoma is found in young children, radiation therapy 
is not desirable due to the detrimental effects on the develop-
ing brain. Thus, there is an urgent need to develop targeted 
therapy based on the underlying biology. C11orf95-RELA 
fusion was found to be the most recurrent structural variation 
in approximately 70% of supratentorial ependymomas (ST-
EPN) [14, 15]. Neural stem cells transformed by C11orf95-
RELA were able to form brain tumor in mice [11, 14]. How-
ever, how C11orf95-RELA functions in tumorigenesis at 
the molecular level is largely unknown. We present results 
here showing that contrary to the hypothesis that C11orf95-
RELA ependymoma is driven by the RELA component of 
the fusion, binding affinity of the fusion protein to DNA is 
dictated by the C11orf95 component. The contribution of 
the RELA component is to stabilize the DNA binding of 
the fusion protein and provide its activation domain to drive 
expression of the target genes.Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0040 1-020-02225 -8) contains 
supplementary material, which is available to authorized users.
 * Albert Wu Cheng 
 albert.cheng@jax.org
 * Ching C. Lau 
 ching.lau@jax.org
1 The Jackson Laboratory for Genomic Medicine, Farmington, 
CT, USA
2 Texas Children’s Cancer Center, Baylor College of Medicine, 
Houston, TX, USA
3 Department of Pediatrics, Northwestern University, Chicago, 
IL, USA
4 The Jackson Laboratory Cancer Center, Bar Harbor, ME, 
USA
5 Department of Genetics and Genome Sciences, University 
of Connecticut Health Center, Farmington, CT, USA
6 Institute for Systems Genomics, University of Connecticut 
Health Center, Farmington, CT, USA
7 Division of Hematology-Oncology, Connecticut Children’s 
Medical Center, Hartford, CT, USA
8 Department of Pediatrics, University of Connecticut Health 
Center, Farmington, CT, USA




HEK293T and its derived G16-2, G16-3, G16-4 cells as 
well as BXD-1425-EPN cells were cultured in Dulbecco’s 
modified Eagle’s medium (Sigma) with 10% fetal bovine 
serum (Lonza), 4% Glutamax (Gibco), 1% sodium pyruvate 
(Gibco) and penicillin–streptomycin (Gibco). Incubator con-
ditions were 37 °C and 5%  CO2. Protein overexpression in 
G16-2, G16-3 and G16-4 cells were induced by 1 μg/ml 
doxycycline treatment for 2 days.
Virus production
A viral packaging mix of pLP1, pLP2, and VSV-G were 
co-transfected with each lentiviral vector (pCW-RELA-HA, 
pCW-C11orf95fus1-HA, or pCW-C11orf95-RELAfus1-HA) 
into Lenti-X 293T cells (Clontech), seeded the day before 
in 6-well plates at a concentration of 1.2 × 106 cells per 
well, using Lipofectamine 3000 (ThermoFisher). Media 
was changed 6 h after transfection then incubated overnight. 
Twenty-eight hours post transfection, the media supernatant 
containing virus was filtered using 45 μm PES filters then 
stored at − 80 °C until use.
Cell line generation
To make G16-2, G16-3, and G16-4 cell lines, the day prior 
to transduction, HEK293T cells were seeded into 12-well 
plates at a density of 1.5 × 105 cells per well. Prior to trans-
duction, media was changed to that containing 10 μg/ml 
polybrene, 1 ml per well. 250 μl of each respective virus 
was added to each well and incubated overnight. Media was 
changed 24 h post-transduction. Four days post-transduc-
tion, cells were split. Five days post-transduction, media 
with antibiotics (2 μg/ml Puromycin) was added to each 
respective well of one replicate plate. Antibiotic selection 
continued for at least 2 weeks before use in downstream 
experiments.
Cloning
ORF encoding  C11orf95fus1 was obtained as IDT gBlock 
while HEK293T cDNA served as template for amplifying 
RELA sequence. PCR and SLIC cloning were used to insert 
ORF encoding  C11orf95fus1, C11orf95-RELAfus1, RELA 
with C-terminal HA tag into Gateway donor vector (pCR8/
GW/TOPO, Invitrogen). Then LR clonase II reactions were 
used to shuttle ORFs into pCW-DEST (lentiviral Dox-
inducible expression) derived from pCW-Cas9 (Addgene # 
50661), and pmax-DEST (transient constitutive expression, 
Addgene # 48222) vectors, generating pCW-C11orf95fus1-
HA, or pCW-C11orf95-RELAfus1-HA, pCW-RELA-HA len-
tiviral Dox-inducible plasmids and pmax-C11orf95fus1-HA, 
pmax-C11orf95-RELAfus1-HA, pmax-RELA-HA transient 
expression plasmids. pmax-Clover and pmax-C11orf95-
Clover, and pmax-C11orf95fus1-VP64, pmax-mScarlet-
H2A, plasmids were generated with a combination of PCR, 
restriction-ligation, SLIC and LR Clonase II reactions. 
GFP-reporter plasmids, 15xUSF1-minCMV-EGFP and 
15xC11orf95-minCMV-EGFP, were generated by ligation of 
annealed oligos containing USF1 or C11orf95 binding sites 
into minCMV-EGFP plasmid with non-palindromic over-
hang sites via digestion with BsaI, subsequently screened for 
the number of binding sites by Sanger sequencing.
Transfection and imaging
Cells were seeded into 12-well plates at a density of 
1.5 × 105 cells per well the day before transfection. For 
imaging experiments, 300 ng of pmax-C11orf95fus1-Clover 
or pmax-Clover (unfused control) was co-transfected with 
100 ng of pmax-mScarlet-H2A (nuclear marker) using 1.5 
µL Attractene transfection reagent (Qiagen). Microscopy 
images were taken with the iRiS Digital Cell Imaging Sys-
tem (Logos Biosystems).
Flow cytometry
GFP-reporter plasmid DNA (300 ng) containing 15xUSF1 
binding sites (15xUSF1-minCMV-EGFP) or 15xC11orf95 
binding sites (15xC11orf95-minCMV-EGFP) was co-trans-
fected with 300 ng of plasmid expressing test transcription 
factor constructs (EmptyVector, pmax-C11orf95fus1, pmax-
C11orf95-RELAfus1, pmax-RELA, pmax-C11orf95fus1-
VP64) using 1.5 µl Lipofectamine 3000 (ThermoFisher). 
48 h after transfection, cells were trypsinized, suspended in 
media then analyzed on a LSRFortessa X-20 flow cytometer 
(BD Bioscience). Fifty thousand events were collected each 
run.
Western blot
Western blot was performed using general protocol from 
Bio-Rad. Primary antibodies used were HA antibody (Cell 
Signaling Technology 3724S), RELA antibody (Abcam 
ab32536), and β-actin antibody (Cell Signaling Technology 
4970S).
Genotyping
BXD-1425-EPN DNA was extracted using DNeasy Blood 
& Tissue Kit (Qiagen), followed by genotyping PCR using 
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Phusion PCR protocol (NEB) with primer pair of forward: 
CCT GCA CCT GGA CGA CAT and reverse: TTG GTG GTA 
TCT GTG CTC CTC. PCR amplicons were sent for Sanger 
sequencing, and analyzed by ApE.
Gene ontology analysis
Gene ontology analysis was done with Metascape (https ://
metas cape.org/).
DNA motif analysis
ChIP-seq peak sequences were uploaded and analyzed by 
MEME-ChIP (https ://meme-suite .org/tools /meme-chip). 
Motifs were found de novo by DREAM. Sequences that had 
specific motif were reported by FIMO.
RNA‑seq and analysis
RNA was extracted using RNeasy Mini Kit (Qiagen), then 
sent to Genewiz for library construction and sequencing by 
Illumina Nextseq sequencer. Each sample had two biological 
replicates. RNA-seq data was quantified using Salmon (ver-
sion 0.8.0), followed by differential expression analysis using 
DEseq2. The cutoff for identifying differentially expressed 
genes were set as FDR < 0.05 and fold change ≥ 1.5.
ChIP‑seq and analysis
ChIP was performed using iDeal ChIP-seq kit for Transcrip-
tion Factors (Diagenode) and protocol provided. HA (Cell 
Signaling Technology 3724S), RELA (Abcam ab32536) 
and H3K27ac (Cell Signaling Technology 8173S) antibod-
ies were used for chromatin pull-down. Libraries were con-
structed using KAPA Hyper Prep Kits (Roche) and NEB-
Next® Multiplex Oligos for Illumina® (NEB) for Illumina 
Nextseq sequencing. Each sample had two biological rep-
licates. The reproducibility between replicates was evalu-
ated by Pearson correlation coefficient of read counts using 
deepTools (version 3.3.0) which was all greater than 0.95. 
Replicates were then combined for peak calling.
Sequencing data was mapped to hg38 reference genome 
by Bowtie2 (version 2.3.1). Sequences with mapping quality 
score greater than ten were accepted for the following analy-
sis. Peaks were called by MACS2 (version 2.1.0.20151222) 
using “–q 0.01 –nomodel –extsize 200” parameter for 
transcription factor ChIP-seq, and using “–broad −q 0.05, 
–nomodel –extsize 220” for histone mark ChIP-seq. For 
peaks that had at least 1 bp overlap, we considered them 
as overlapped peaks. The peak was considered to locate at 
gene promoter when it had at least 1 bp overlap with the 
promoter region. Promoter region was defined as a 5 kb 
span extending 2.5 kb at both sides from the transcription 
start site (TSS). Differential H3K27ac peaks were called 
by MACS2 bdgdiff subcommand. Read density heatmap of 
ChIP-seq peaks were computed and plotted using deepTools 
(version 3.3.0). Data was viewed by Integrative Genomics 
Viewer (IGV).
HiChIP and analysis
HiChIP was performed following protocol published by 
Mumbach et al. 2017, with minor modifications. HA (Cell 
Signaling Technology 3724S) and H3K27ac (Cell Signal-
ing Technology 8173S) antibodies were used for chromatin 
pull-down. Libraries were constructed using KAPA Hyper 
Prep Kits (Roche) and NEBNext® Multiplex Oligos for 
Illumina® (NEB) for Illumina Novaseq sequencing. Each 
sample had two biological replicates. Replicate data was 
combined for analysis. Raw data was processed by HiC-Pro 
[17] using hg38 reference genome. Chromatin interactions 
were called using hichipper [6] by providing certain ChIP-
seq peaks and HiC-Pro outputs. Interaction heatmap was 
plotted by HiCPlotter [1] at 10 kb resolution. Interactions 
associated with specific genes were filtered by interaction 
count greater than one, then visualized on WashU Epige-
nome Browser, or processed for enhancer-promoter analysis.
Canonical pathway analysis
Canonical pathway analysis was done by Ingenuity Pathway 
Analysis (IPA) using “Core Analysis” function.
Results
C11orf95‑RELA is a novel transcription factor 
that recognizes a specific DNA motif dictated 
by the C11orf95 fragment
C11orf95-RELAfus1 was identified as the most frequently 
occurring fusion subtype in supratentorial ependymoma 
with C11orf95-RELA fusion (ST-EPN-RELA), containing 
almost the entire RELA gene except the first two codons 
fused to a truncated C11orf95 gene fragment (C11orf95fus1) 
harboring two and a half exons out of five exons of the full-
size gene [14]. Unlike RELA, which is a well-known tran-
scription factor subunit of NF-κB, C11orf95 is an unchar-
acterized protein. While nuclear localization of RELA is 
dependent on NF-κB activation, C11orf95-RELA fusion 
protein is constitutively localized in the nucleus in trans-
formed HEK293T and mouse neural stem cells [14]. Intrigu-
ingly, C11orf95fus1 contains a  C2H2 zinc finger domain typi-
cally found in transcription factors (Supplementary Fig. 1, 
online resource), implying its DNA binding potential. We 
hypothesized that the fusion of C11orf95 and RELA create 
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a novel transcription factor whose DNA binding affinity 
as well as nuclear localization are largely governed by the 
C11orf95 fragment. Interestingly, fusion of  C11orf95fus1 
fragment to GFP is sufficient to drive exclusive localiza-
tion of the fluorescence signal in the nucleus of HEK293T 
cells, demonstrating the intrinsic propensity of the C11orf95 
fus1 fragment to translocate into the nucleus (Supplemen-
tary Fig. 2, online resource). However, there was previ-
ously no direct evidence for the binding of  C11orf95fus1 and 
C11orf95-RELAfus1 to DNA. To address this question and 
further decipher the regulatory mechanisms of the fusion 
protein, we engineered HEK293T cell lines to express 
C11orf95-RELAfus1 (G16-4),  C11orf95fus1 fragment (G16-
3), or the RELA fragment (G16-2) in order to study the 
contribution of the fusion protein and each of the partners 
to epigenetic program and transcriptional regulation. These 
transgenes are tagged with the HA-epitope and are under the 
control of a doxycycline-inducible TetO promoter (Supple-
mentary Fig. 3a, b, online resource). The HA tag facilitates 
our molecular experimentations such as Western blot and 
ChIP, despite the lack of good quality antibodies against 
the fusion and C11orf95 proteins. We then conducted ChIP-
seq using HA antibody to profile genome-wide chromatin 
bindings of RELA,  C11orf95fus1 and C11orf95-RELAfus1 
in G16-2, G16-3 and G16-4 cells, respectively. Surpris-
ingly, 32,152 and 38,428 binding peaks were identified for 
C11orf95-RELAfus1 and  C11orf95fus1, respectively, with 
16,829 overlapping (Fig. 1a). In contrast, RELA ChIP-
seq only identified 111 binding sites in total. Considering 
RELA is normally inactive without cellular stimulation, we 
treated G16-2 cells with tumor necrosis factor (TNF) for 
six hours after doxycycline induction of RELA expression, 
in order to capture RELA bindings in its active state. As a 
result, 1542 binding peaks were identified, which was still 
far fewer than the binding peaks identified for the fusion or 
C11orf95. Among the RELA binding peaks identified in the 
presence of TNF stimulation, less than 25% overlapped with 
C11orf95-RELAfus1 peaks (Fig. 1a). These results indicate 
that  C11orf95fus1 contributes to the majority of DNA bind-
ing of the fusion protein.
Although both  C11orf95fus1 and C11orf95-RELAfus1 
can bind to DNA, their binding targets were not com-
pletely identical. Other than the common peaks, there were 
also specific peaks for each of the two proteins (Fig. 1a). 
Among the 16,829 shared peaks, C11orf95-RELAfus1 had 
significantly higher signal densities than  C11orf95fus1 after 
sequencing read normalization (Fig. 1b), suggesting the 
RELA portion of the fusion protein might stabilize DNA 
Fig. 1  a Venn diagram of ChIP-seq peaks. The DNA pull-down were 
done by RELA-HA (blue, the smallest circle) in G16-2 cells, RELA-
HA after TNF treatment (magenta) in G16-2 cells,  C11orf95fus1-HA 
(green) in G16-3 cells and C11orf95-RELAfus1-HA (red) in G16-4 
cells. The numbers indicate the total peaks identified in each cohort. 
The Venn diagram is not dawn to scale. b Read densities over ChIP-
seq peaks of  C11orf95fus1 and C11orf95-RELAfus1. Using peak sum-
mit as the center, the normalized mapped reads over a 1  kb region 
around the peak were plotted for a total of 16,829 shared peaks of 
 C11orf95fus1 and C11orf95-RELAfus1. c Gene ontology analysis 
on  C11orf95fus1 and C11orf95-RELAfus1 common binding genes, 
 C11orf95fus1 unique binding genes and C11orf95-RELAfus1 unique 
binding genes. The top three ranked biological processes according to 
q value are shown
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binding. Furthermore, we selected genes that were bound by 
 C11orf95fus1 and/or C11orf95-RELAfus1 at promoter regions, 
categorized them into three groups:  C11orf95fus1 and 
C11orf95-RELAfus1 common binding genes,  C11orf95fus1 
unique binding genes and C11orf95-RELAfus1 unique bind-
ing genes. Gene ontology (GO) analysis showed C11orf95-
RELAfus1 unique binding genes were specifically enriched 
in neuron projection morphogenesis, actin filament process 
and skeletal system morphogenesis, which are known to 
be associated with brain or brain disease development [3, 
7, 16, 18].  C11orf95fus1 and C11orf95-RELAfus1 common 
binding genes were enriched in cell cycle arrest, regulation 
of autophagy and regulation of mitochondrion organiza-
tion. However,  C11orf95fus1 unique binding genes were 
enriched in more fundamental biological processes such 
as translation, carbohydrate derivative biosynthetic pro-
cess and asparagine N-linked glycosylation (Fig. 1c, Sup-
plementary Table 1, online resource). In addition, we also 
obtained gene expression profiles of G16-3 and G16-4, as 
well as HEK293T control cells by RNA-seq to interrogate 
the transcriptional effects of  C11orf95fus1 and C11orf95-
RELAfus1. Sixty-six and 210 genes were identified to be 
up-regulated (FDR < 0.05, fold change ≥ 1.5) in G16-3 and 
G16-4 cells, respectively, compared to the controls. In par-
allel, we compiled a list of 886 ST-EPN-RELA-associated 
genes (Supplementary Table 2, online resource) based on 
published data [13, 14, 19]. By comparing G16-3 and G16-4 
up-regulated genes to ST-EPN-RELA-associated genes, only 
three of G16-3  (C11orf95fus1) up-regulated genes overlapped 
with ST-EPN-RELA associated genes, while 67 of G16-4 
(C11orf95-RELAfus1) up-regulated genes overlapped the 
ST-EPN-RELA associated gene list, including some well-
known marker genes such as L1CAM, CHD5 and NOTCH1 
(Supplementary Fig.  4a, b, online resource). All these 
observations collectively indicate that  C11orf95fus1 alone 
is not sufficient to drive transcriptomic dysregulation like 
C11orf95-RELAfus1.
While the HEK293T transgenic cell models allow the 
dissection of the molecular function of C11orf95-RELA 
and its constituents, to obtain insights of the epigenomic 
and transcriptomic effects of C11orf95-RELA in the con-
text of ependymoma, we performed further experiments in 
an ependymoma cell line, BXD-1425-EPN [19] that was 
established from an orthotopic patient-derived xenograft 
(PDX) originating from a ST-EPN-RELA tumor. Genotyp-
ing-sequencing and Western blot experiments with BXD-
1425-EPN identified a novel fusion configuration contain-
ing the first three exons and a small fragment of the fourth 
exon of C11orf95 gene, and RELA without the first two 
and half exons (Supplementary Fig. 3c, online resource), 
here referred to as C11orf95-RELA1425. Despite the lack of 
fusion-specific antibody, the fact that unstimulated RELA 
is excluded from the nucleus [5] while the fusion protein 
binds to DNA allowed us to use anti-RELA antibody to 
conduct ChIP-seq to pull down C11orf95-RELA1425 bound 
chromatin. RELA ChIP-seq in BXD-1425-EPN cells identi-
fied 13,954 chromatin binding sites of C11orf95-RELA1425, 
with 5,338 commonly shared by C11orf95-RELAfus1 bind-
ings in G16-4 cells. With the binding peak sequences of 
 C11orf95fus1, C11orf95-RELAfus1 and C11orf-RELA1425, 
we implemented de novo motif discovery using MEME-
ChIP tool [8]. An identical GC-rich motif (GTG GCC CC) 
was readily recovered with top scores from all three sets of 
ChIP-seq peak sequences (Fig. 2a), supporting the validity 
of fusion protein pull-down by RELA antibody in BXD-
1425-EPN cells and further confirming that the  C11orf95fus1 
fragment dictates DNA binding specificity of the fusion 
protein. As the motif consensus was repeatedly enriched by 
using different cells with different types of C11orf95-RELA 
fusion and different antibodies, the identified C11orf95 bind-
ing specificity is highly faithful. To establish GTG GCC 
CC as the bona fide DNA binding motif of C11orf95, we 
performed a reporter assay with 15 copies of GTG GCC 
CC and a minimum promoter cloned upstream of an EGFP 
reporter gene (Fig. 2b). As expected, C11orf95-RELAfus1 
activated EGFP reporter expression harboring copies of 
the putative C11orf95 motif. On the contrary, the unfused 
constituents RELA or  C11orf95fus1 were unable to activate 
the reporter. Furthermore, supplementing  C11orf95fus1 
with a heterologous VP64 activation domain in the form 
of  C11orf95fus1-VP64 fusion endowed transactivation activ-
ity on the reporter with 15 copies of the putative C11orf95 
(GTG GCC CC) DNA binding motif but not on a control 
reporter harboring 15 copies of an unrelated USF1 motif. 
These results suggest that  C11orf95fus1 binds to the GC-rich 
motif GTG GCC CC and may activate gene expression by 
hijacking the transcriptional activation domain of RELA, 
as in the case of the C11orf95-RELA fusion. Furthermore, 
to examine the functional region of  C11orf95fus1, we con-
structed three truncation mutants of  C11orf95fus1-VP64 
fusions and performed reporter assay to measure their trans-
activation activities (Supplementary Fig. 5, online resource). 
Deletion of the zinc finger (ZF) domain led to the loss of 
transactivation activity. In addition, deletion of the N-ter-
minal and C-terminal regions upstream and downstream of 
the ZF domain also resulted in the loss of transactivation 
activity (Supplementary Fig. 5, online resource), suggesting 
 C11orf95fus1 might be the minimal fragment of C11orf95 
required for DNA binding. These results and the observation 
by Parker et al. [14] that  C11orf95fus1 is the most frequent 
breakpoint of C11orf95 and is contained in all identified 
C11orf95-RELA fusion subtypes prompted us to speculate 
that  C11orf95fus1 is the minimal fragment required for a 
functional C11orf95-RELA fusion.
Among the top-scoring ChIP-seq peaks of C11orf95-
RELAfus1 and C11orf95-RELA1425, approximately half of 
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them contain one or more of the C11orf95 DNA binding motif 
(Fig. 2c), implying a direct binding by the fusion protein. The 
no-motif peaks might be bound by a C11orf95-RELA-contain-
ing protein complex that uses another pioneer subunit to initi-
ate chromatin binding. Both motif and no-motif peaks were 
distributed at either promoter or non-promoter region with no 
significant bias (Fig. 2c). Interestingly, ChIP-seq experiments 
in G16-4 and BXD-1425-EPN cells identified fusion bind-
ing peaks at C11orf95 promoter and RELA transcription end 
sites, with the C11orf95 DNA binding motif observed in both 
peaks (Fig. 2d), suggesting the possibility of auto-regulation. 
To evaluate such hypothesis, we determined whether expres-
sion of endogenous C11orf95 in G16-4 cells was induced by 
exogenous C11orf95-RELAfus1 provided by the transgene. The 
alternative codon usage adopted in the C11orf95fus1 transgene 
construction allowed us to encode the same  C11orf95fus1 pro-
tein sequence with synonymous codons for distinguishing 
sequencing reads derived from transgenic and endogenous 
C11orf95 in RNA-seq experiments (Supplementary Fig. 1, 
online resource). A two-fold up-regulation of endogenous 
C11orf95 transcripts was observed in G16-4 but not in G16-3 
cells after doxycycline induction, validating the potential of 
C11orf95-RELA to positively auto-regulate its expression via 
binding to the C11orf95 promoter (Supplementary Fig. 4b, 
online resource).
C11orf95‑RELA modulates chromatin state 
and mediates chromatin interaction
We applied H3K27ac ChIP-seq to profile active chromatin 
regions in HEK293T transgenic cell models and BXD-1425-
EPN to address the correlation between the fusion protein 
binding and chromatin state. At 3,792 fusion protein binding 
sites with top confidence in BXD-1425-EPN cells, strong 
H3K27ac signals were observed (Fig. 3a). Comparative anal-
ysis of genome-wide H3K27ac profiles between transgenic 
HEK293T cell models expressing fusion (G16-4) and RELA 
(G16-2) identified 441 differential H3K27ac peaks specific 
in G16-4 cells. These G16-4 specific H3K27ac peaks highly 
correlated with fusion protein binding (Fig. 3b) with over 
90% of them overlapping with fusion protein binding sites, 
implying the C11orf95-RELA was able to initiate chromatin 
state changes. CCND1 and L1CAM, two well-known marker 
genes of ST-EPN-RELA, exemplify two different chroma-
tin state outcomes upon fusion protein binding. At L1CAM 
promoter region, fusion protein binding likely resulted in 
the deposition of H3K27ac marks (Fig. 3c). On the contrary, 
CCND1 promoter retained its active chromatin state regard-
less of the presence (in G16-4 and BXD-1425-EPN cells) 
or absence (in G16-2 and G16-3 cells) of the fusion protein 
binding (Fig. 3c).
As three-dimensional chromatin structure is known to be 
tightly associated with disease and cancer development, we 
next sought to identify changes in genome structure medi-
ated by the fusion in ST-EPN-RELA. We utilized a sequenc-
ing-based chromatin capture approach HiC Chromatin 
Fig. 2  a DNA binding motifs enriched for  C11orf95fus1 and 
C11orf95-RELAfus1 and C11orf95-RELA1425 in G16-3, G16-4 and 
BXD-1425-EPN cells, respectively. b Reporter assay. Reporter EGFP 
gene was linked to identified C11orf95 binding motif as well as USF1 
motif as control. Empty vector (EV), C11orf95-RELAfus1,  RELA, 
 C11orf95fus1 or activation domain VP64 fused  C11orf95fus1 were 
expressed to test EGFP expression. EGFP signals were measured by 
flow cytometry. c C11orf95 binding motif distribution in C11orf95-
RELA peaks in G16-4 and BXD-1425-EPN cells. d RELA, 
 C11orf95fus1, C11orf95-RELAfus1 and C11orf95-RELA1425 binding 
profiles at C11orf95 and RELA genes. The orange bars indicate the 
regions that have C11orf95 binding motifs
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Immunoprecipitation (HiChIP) [10] to characterize genome-
wide chromatin interactions and connect the protein binding 
peaks into loops and networks. We used anti-HA antibody 
to perform HiChIP of HA-tagged fusion protein in G16-4 
cell lines. By further filtering with C11orf95-RELAfus1-HA 
ChIP-seq peaks, we identified a total of 32,669 high-confi-
dence interactions. For BXD-1425-EPN cells, we performed 
H3K27ac HiChIP and identified 15,777 C11orf95-RELA1425 
mediated interactions filtered by both H3K27ac and RELA 
ChIP-seq peaks. We mapped HiChIP identified chromatin 
interactions to the promoter regions of 886 ST-EPN-RELA 
associated genes mentioned above (Supplementary Table 2, 
online resource) to identify ST-EPN-RELA gene associated 
interactions. As a result, a total of 445 common interac-
tions were identified in both G16-4 and BXD-1425-EPN 
cells. Interestingly, not all the 886 genes harbored chroma-
tin interaction(s) to other locus/loci, but only 156 of them 
(Supplementary Table 3, online resource) reached out to 
one or more promoter or non-promoter (enhancer) regions. 
Since these ST-EPN-RELA gene associated chromatin inter-
actions were directly mediated by the fusion protein, it is 
reasonable to speculate that the more interacting partners 
one gene has, the more regulatory events it is involved in, 
and the more important roles it plays in ST-EPN-RELA. 
In other words, the genes that have more interactions with 
other genomic loci are more likely to be the hub of the fusion 
protein mediated network and more delicately regulated in 
fusion-associated transcription, so that they might contrib-
ute more to ependymoma development. Hence, we counted 
the number of interactions each gene promoter is involved 
in and plotted a histogram ranking the 156 genes by their 
interaction counts (Fig. 4a). The top-ranking genes included 
CACNA1H, MAFG, NOTCH1, GPSM1, MXRA8, PYCR1, 
VWA1 and RXRA. Of note, CACNA1H is a calcium channel 
gene previously implicated and experimentally validated to 
be important in ST-EPN-RELA cell survival [9], support-
ing the validity of our strategy in grading the significance 
of the genes. NOTCH1 and GPSM1 encode membrane pro-
teins critical for Notch signaling and G-protein signaling, 
respectively, suggesting the involvement of these signal-
ing pathways in ependymoma development in addition to 
NF-κB pathway that has received the most attention. To 
comprehensively nominate ependymoma-associated sign-
aling pathways, we conducted a canonical pathway analysis 
with the genes that have more than one interacting chromatin 
site using Ingenuity Pathway Analysis (Qiagen) (Fig. 4b). 
Interestingly, the top enriched pathway was Notch signal-
ing. Looking back at the ST-EPN-RELA gene list (Supple-
mentary Table 2, online resource), 15 Notch signaling genes 
stood out, ADAM12, CCND1, DLK1, DVL1, DVL2, HDAC1, 
HES1, HES5, JAG1, JAG2, LFNG, LNX1, MFAP2, NOTCH1 
and PSENEN, further demonstrating Notch signaling might 
play a significant role in ST-EPN-RELA oncogenesis [2].
As we mentioned above, the fusion protein not only 
mediates promoter-promoter interactions but also enhancer-
promoter interactions. To this end, we again made use of 
the 445 ST-EPN-RELA gene associated chromatin interac-
tions identified in both G16-4 and BXD-1425-EPN cells, 
but focusing on the 91 non-promoter (putative enhancer) 
regions (Supplementary Table 4, online resource). We then 
counted the number of gene promoters connecting to these 
91 enhancers. Although the majority of the enhancers had 
Fig. 3  a ChIP-seq read densities of C11orf95-RELA1425 and 
H3K27ac in BXD-1425-EPN cells. 3792 top-scoring C11orf94-
RELA1425 ChIP-seq peaks were used to plot the heatmap. The left 
side heatmap showed C11orf95-RELA1425 signals along a 5 kb region 
centering the peak summit. The right side heatmap showed H3K27ac 
signals along the same regions. b Read densities of H3K27ac and 
C11orf95-RELAfus1 in G16-4 cells. 441 differential H3K27ac peaks 
in G16-4 compared to G16-2 cells were used to plot the heatmap. 
The left side heatmap showed H3K27ac signals along a 5 kb region 
centered with H3K27ac peak center. The right side heatmap showed 
C11orf95-RELAfus1 signals along the same regions. c RELA, 
 C11orf95fus1, C11orf95-RELAfus1 and C11orf95-RELA1425 as well as 
corresponding H3K27ac ChIP-seq profiles at ST-EPN-RELA marker 
genes CCND1 and L1CAM 
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only one interacting promoter, some of them interacted with 
two to seven promoters (Supplementary Fig. 6a, online 
resource). The enhancer with the highest number of pro-
moter interactions is located in the intron of ASPSCR1 gene 
on chromosome 17, connecting with ASPSCR1, DCXR, 
MAFG, MAFG-AS1, NPB, PYCR1 and RAC3 genes (Sup-
plementary Fig. 6b, online resource). More impressively, 
another distal enhancer had robust interactions with pro-
moters of NOTCH1 and GPSM1 genes in both G16-4 and 
BXD-1425-EPN cells. Fusion protein binding was intensive 
and resulted in H3K27ac deposition at the enhancer region 
in G16-4 and BXD-1425-EPN cells (Fig. 4c). This suggests 
a potential regulatory scenario in which the fusion protein 
induces epigenetic changes at an enhancer and mediates 
chromatin reorganization with key genes of two distinct 
arms of signaling, specifically the Notch and G-protein 
signaling pathways, to initiate genetic programs underlying 
ST-EPN-RELA pathogenesis.
Discussion
Informed by our study of epigenetic reprogramming driven 
by C11orf95-RELA fusion in HEK293T cell models and 
ependymoma cell line, we gained important knowledge 
in the molecular mechanisms underlying tumorigenesis 
driven by a single oncogenic C11orf95-RELA fusion [11, 
14, 15]. Although the overexpression of  C11orf95fus1 
alone in HEK293T cells was not sufficient to drive epend-
ymoma-like transcriptomic transformation, the ChIP-seq 
with both HEK293T and BXD-1425-EPN cells shows 
that the C11orf95 portion of the fusion plays a critical 
role binding to DNA and thus serving as a shuttle for the 
entry of RELA to the nucleus. By recognizing a specific 
DNA motif, C11orf95 portion targets particular genes 
and regulates their expression by hijacking the activation 
domain of RELA. Other than RELA, there was indica-
tion that C11orf95 also fused to other transcription factors 
such as YAP1 [12, 14] in ST-EPN-RELA, further imply-
ing the driving role of C11orf95. Since the first discovery 
of C11orf95-RELA mutation in ST-EPN, NF-κB path-
way caught the most attention in tumorigenesis signaling 
Fig. 4  a Histogram of interaction counts per gene. The interactions 
coming out from the 156 identified gene promoters were counted. 
b Canonical pathway analysis of 102 genes that had more than one 
interaction. The numbers by the pathways are p values. c Chromatin 
interactions captured by HiChIP along NOTCH1 and GPSM1 genes. 
The heatmaps showed a 1 Mb region of interactions along NOTCH1 
and GPSM1 genes. The browser view showed the zoom-in details of 
the black box indicating region in the heatmaps, including ChIP-seq 
profiles and HiChIP interactions. The green bars indicate NOTCH1 
and GPSM1 promoters. The orange bar indicates the enhancer
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[14, 15]. However, it is not the only pathway involved in 
ST-EPN-RELA [11]. Suggested by our chromatin inter-
action analysis in HEK293T and BXD-1425-EPN cell 
models, Notch signaling ranked among the top pathways 
involved in ST-EPN-RELA development, as a number of 
Notch genes were identified as chromatin hubs harbor-
ing more than one distal interacting partners. However, 
when we applied Notch inhibitor to treat BXD-1425-EPN 
cells, no significant effect on cell survival and growth 
was observed (data not shown). de Almeida Magalhães 
T et al. also had the same observation in their study [2]. 
They claimed although Notch inhibitor treatment did not 
change cell proliferation, apoptosis and colony formation 
of ST-EPN-RELA, it induced down-regulation of cancer 
stem cell markers. Therefore, we speculate on two possible 
scenarios regarding the roles of Notch signaling. The first 
possibility is that Notch signaling is not required for EPN 
cell maintenance, though it is essential for EPN develop-
ment, as other signaling pathways may play substitutional 
roles such as the NF-κB and G-protein signaling path-
ways. Of note, NF-κB inhibitor alone did not change cell 
viability in ST-EPN-RELA, either [4], suggesting perhaps 
combinatorial treatment targeting multiple pathways could 
be pursued for ST-EPN-RELA therapeutics. Another pos-
sibility is that the efficacy of Notch inhibitor treatment on 
cell lines could be different from that of in vivo treatment 
in mice or human, since the microenvironment might be 
critical in determining the response of the cancer cells to 
treatment. The roles of the Notch, NF-κB, and G-protein 
pathways in EPN will warrant further in vivo investiga-
tions using single agent or combinations of inhibitors. 
Another interesting finding of this study is that other than 
the direct binding to gene promoters, C11orf95-RELA also 
bind to regulatory elements such as enhancers by chro-
matin interaction analysis. The enhancers identified to 
interact with multiple ST-EPN-RELA genes are potential 
targets for therapeutic interventions. Specifically, by dis-
rupting one particular enhancer, more than one ST-EPN-
RELA genes could be affected, providing a more efficient 
way to manipulate gene expression in ependymoma. While 
the present work presents the first epigenomic and tran-
scriptomic characterization of the genetic program induced 
by the C11orf95-RELA fusion protein, future works on 
additional ST-EPN-RELA cell lines and primary tumors 
will further establish the core program as well as subtype 
differences critical for the development of precision and 
personalized therapeutics for this devastating cancer.
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